244 related articles for article (PubMed ID: 24731945)
1. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
[TBL] [Abstract][Full Text] [Related]
2. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Constantinescu SE; Constantinescu CS
Expert Rev Clin Pharmacol; 2016; 9(1):49-57. PubMed ID: 26536299
[TBL] [Abstract][Full Text] [Related]
3. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Hainke U; Thomas K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
[TBL] [Abstract][Full Text] [Related]
4. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Aharoni R; Saada R; Eilam R; Hayardeny L; Sela M; Arnon R
J Neuroimmunol; 2012 Oct; 251(1-2):14-24. PubMed ID: 22749337
[TBL] [Abstract][Full Text] [Related]
5. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Brück W; Zamvil SS
Expert Rev Clin Pharmacol; 2012 May; 5(3):245-56. PubMed ID: 22697588
[TBL] [Abstract][Full Text] [Related]
6. Oral laquinimod treatment in multiple sclerosis.
Fernández O
Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
[TBL] [Abstract][Full Text] [Related]
7. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.
Schulze-Topphoff U; Shetty A; Varrin-Doyer M; Molnarfi N; Sagan SA; Sobel RA; Nelson PA; Zamvil SS
PLoS One; 2012; 7(3):e33797. PubMed ID: 22479444
[TBL] [Abstract][Full Text] [Related]
8. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
9. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.
Kaye J; Piryatinsky V; Birnberg T; Hingaly T; Raymond E; Kashi R; Amit-Romach E; Caballero IS; Towfic F; Ator MA; Rubinstein E; Laifenfeld D; Orbach A; Shinar D; Marantz Y; Grossman I; Knappertz V; Hayden MR; Laufer R
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6145-E6152. PubMed ID: 27671624
[TBL] [Abstract][Full Text] [Related]
10. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Brunmark C; Runström A; Ohlsson L; Sparre B; Brodin T; Aström M; Hedlund G
J Neuroimmunol; 2002 Sep; 130(1-2):163-72. PubMed ID: 12225898
[TBL] [Abstract][Full Text] [Related]
11. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.
Wilmes AT; Reinehr S; Kühn S; Pedreiturria X; Petrikowski L; Faissner S; Ayzenberg I; Stute G; Gold R; Dick HB; Kleiter I; Joachim SC
J Neuroinflammation; 2018 Jun; 15(1):183. PubMed ID: 29903027
[TBL] [Abstract][Full Text] [Related]
12. Insight into the mechanism of laquinimod action.
Brück W; Wegner C
J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
14. Review of laquinimod and its therapeutic potential in multiple sclerosis.
Thöne J; Gold R
Expert Opin Pharmacother; 2013 Dec; 14(18):2545-52. PubMed ID: 24215556
[TBL] [Abstract][Full Text] [Related]
15. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Ruffini F; Rossi S; Bergamaschi A; Brambilla E; Finardi A; Motta C; Studer V; Barbieri F; De Chiara V; Hayardeny L; Comi G; Centonze D; Martino G
Mult Scler; 2013 Jul; 19(8):1084-94. PubMed ID: 23232603
[TBL] [Abstract][Full Text] [Related]
16. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
17. Laquinimod in the treatment of multiple sclerosis: a review of the data so far.
Thöne J; Linker RA
Drug Des Devel Ther; 2016; 10():1111-8. PubMed ID: 27042003
[TBL] [Abstract][Full Text] [Related]
18. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
Lund BT; Kelland EE; Hayardeny L; Barilan O; Gilmore W; Weiner LP
J Neuroimmunol; 2013 Oct; 263(1-2):108-15. PubMed ID: 23920036
[TBL] [Abstract][Full Text] [Related]
19. Oral laquinimod therapy in relapsing multiple sclerosis.
Preiningerova J
Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
[TBL] [Abstract][Full Text] [Related]
20. Laquinimod enhances central nervous system barrier functions.
Lühder F; Kebir H; Odoardi F; Litke T; Sonneck M; Alvarez JI; Winchenbach J; Eckert N; Hayardeny L; Sorani E; Lodygin D; Flügel A; Prat A
Neurobiol Dis; 2017 Jun; 102():60-69. PubMed ID: 28235673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
